Log In
Print
BCIQ
Print
Print this Print this
 

Long Acting rFactor lX, rFIXFc (Alprolix)

Also known as: FIXFc (formerly FIX:Fc)

  Manage Alerts
Collapse Summary General Information
Company Biogen Idec Inc.
DescriptionRecombinant fusion protein consisting of human coagulation Factor IX attached to the Fc domain of human IgG1
Molecular Target Factor IX
Mechanism of ActionFactor IX replacement
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentMarketed
Standard IndicationHemophilia
Indication DetailsTreat and prevent bleeding in patients with hemophilia B; Treat hemophilia B; Treat hemophilia B in pediatric patients
Regulatory Designation

U.S. - Orphan Drug (Treat hemophilia B);
U.S. - Undisclosed Review (Treat hemophilia B);
EU - Orphan Drug (Treat hemophilia B);
Japan - Standard Review (Treat and prevent bleeding in patients with hemophilia B);
Australia - Orphan Drug (Treat and prevent bleeding in patients with hemophilia B);
Australia - Standard Review (Treat and prevent bleeding in patients with hemophilia B)

Partner

Swedish Orphan Biovitrum AB; UCB Group


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today